Pfizer stock ends the day slightly higher at the close on the NYSE

On September 21, 2026, Pfizer stock closed at USD 27.66 on the NYSE, up 0.29 percent from the prior session. The move came as investors digested news that Pfizer agreed to share certain overseas drug revenue gains with the U.S. Department of Health and Human Services, which may shape sentiment ahead of upcoming pipeline updates.

Pfizer stock closed at USD 27.66 on the NYSE on September 21, 2026, gaining 0.29 percent from the prior close according to exchange data cited by Zonebourse. The shares thus added modestly to their recent levels while broader health-care names showed mixed moves.

September 21, 2026 in numbers

Pfizer Inc. (ISIN US7170811035, NYSE: PFE) spent the session in a tight range around the USD 27 level, with intraday prices consistent with a close of USD 27.66 per NYSE data. The stock’s advance of 0.29 percent left it broadly in line with recent statistics that had shown the shares at USD 27.66 at the prior close as well, underscoring a period of consolidation. Compared with valuation work cited by GuruFocus, which put an intrinsic value estimate near USD 26.48 per share at a time when the market price stood around USD 27.66, the stock continued to trade at a small premium to that metric, reflecting lingering debate about its longer term earnings power.GuruFocus noted that the valuation gap left the shares roughly 4.5 percent above that GF Value gauge, highlighting a relatively modest divergence rather than an extreme mispricing.

The main fundamental talking point on September 21, 2026 was regulatory and pricing rather than earnings. As Newsquawk reported, Pfizer agreed to share part of increased overseas drug revenue with the U.S. Department of Health under a most favoured nation contract. The provision covers existing medicines from January 1, 2026 through January 20, 2029, with revenue-sharing rates and the list of covered medicines redacted, and with proceeds intended to help lower costs for U.S. patients and taxpayers. That arrangement added a fresh element to the discussion around Pfizer’s pricing strategy and future cash flows even as the stock’s price reaction remained contained. Per NYSE data reflected on Zonebourse, today’s closing print of USD 27.66 fit within the prevailing 52-week range and left the shares trading close to recent lows, underlining how much of the Covid-era premium had already been worked off.Zonebourse also pointed to an after-hours indication near USD 27.76, a marginal uptick of 0.09 percent from the official close, signaling that extended trading remained orderly.

After the bell and next catalysts

In after-hours trading the stock was indicated around USD 27.76 at approximately 6:16 p.m. ET, just 0.09 percent above the regular-session close, according to the same Zonebourse overview, suggesting a calm reaction to the day’s regulatory headlines. Looking ahead, pipeline news remains a focal point for traders. Biotech Reporter highlighted that Pfizer is nearing Phase 2 asthma data for candidate PF-07275315, a development investors are watching closely because respiratory indications could broaden the company’s post-pandemic growth story. Economic calendars and sector commentary on weight-loss and obesity treatments, as seen in reporting from Investing.com, also show how competition in adjacent therapeutic areas could influence sentiment on Pfizer over the coming sessions, even if today’s price move was modest.